What is the 13F Pro Quality Score for FLNA?

13F Pro ranks FILANA THERAPEUTICS, INC. (FLNA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View FLNA's current score at https://13fpro.ai/research/FLNA (free sign-up required for the full ranking).

Where does 13F Pro source FLNA data?

All FILANA THERAPEUTICS, INC. fundamentals and ownership data come directly from SEC EDGAR. FILANA THERAPEUTICS, INC. files with the SEC under CIK 1069530. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is FLNA in?

FILANA THERAPEUTICS, INC. (FLNA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is FLNA research updated on 13F Pro?

FLNA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

FILANA THERAPEUTICS, INC.(FLNA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1069530 FLNA stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

FLNA Stock Analysis & AI Quality Score

AI stock analysis and institutional research for FILANA THERAPEUTICS, INC. (FLNA), a Healthcare sector company. FLNA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), FILANA THERAPEUTICS, INC. reports net income of $-10.3M, free cash flow of $-8.9M. Top institutional holders of FLNA by reported 13-F value include MARSHALL WACE, LLP, TWO SIGMA INVESTMENTS,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. FLNA trades on the Nasdaq exchange and files with the SEC under CIK 1069530. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FLNA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for FILANA THERAPEUTICS, INC. directly from SEC EDGAR.

Net Income

Q1 2026

$-10.3M

Free Cash Flow

Q1 2026

$-8.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Net Income

-273.7% YoY

$-91.0MFY 2025

FY22 $-76.2MFY23 $-97.2MFY24 $-24.3MFY25 $-91.0M

Operating Income

+32.6% YoY

$-95.4MFY 2025

FY22 $-80.0MFY23 $-106.0MFY24 $-141.4MFY25 $-95.4M

EPS (Diluted)

-28.8% YoY

$-1.88FY 2025

FY22 $-1.90FY23 $-2.32FY24 $-1.46FY25 $-1.88

Total Assets

-24.9% YoY

$118.4MFY 2025

FY22 $234.8MFY23 $151.7MFY24 $157.5MFY25 $118.4M

Op. Cash Flow

+72.4% YoY

$-32.3MFY 2025

FY22 $-77.5MFY23 $-82.0MFY24 $-116.9MFY25 $-32.3M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2016	FY 2013
Revenue	—	—	—	—	—	$41.1M
Net Income	$-91.0M -273.7%	$-24.3M +75.0%	$-97.2M -27.5%	$-76.2M -413.4%	$-14.8M -147.1%	$31.5M
Operating Income	$-95.4M +32.6%	$-141.4M -33.5%	$-106.0M -32.4%	$-80.0M -435.0%	$-15.0M -147.7%	$31.4M
EPS (Diluted)	$-1.88 -28.8%	$-1.46 +37.1%	$-2.32 -22.1%	$-1.90	—	$0.70
Total Assets	$118.4M -24.9%	$157.5M +3.9%	$151.7M -35.4%	$234.8M +1116.6%	$19.3M -61.5%	$50.1M
Operating Cash Flow	$-32.3M +72.4%	$-116.9M -42.6%	$-82.0M -5.8%	$-77.5M -533.6%	$-12.2M	—

AI Insight: FLNA Financial Trends

Equity has eroded from $189M to $68M over seven quarters as FLNA burns cash with zero revenue reported.

• Equity has declined steadily every quarter, falling from $189M in Q2 2024 to $68M in Q1 2026 — a 64% reduction.

• Operating losses have moderated recently: op income improved from -$45M in Q2 2025 to -$11M in Q1 2026.

• Operating cash outflows peaked at -$61M in Q4 2024 but have since stabilized near -$9M to -$10M in recent quarters.

⚠ No revenue reported across all eight quarters; without a revenue catalyst, equity depletion will continue.

⚠ Equity at $68M in Q1 2026 with persistent cash burn raises near-term funding and runway concerns.

⚠ Debt data is absent across all periods; any undisclosed leverage would materially worsen the liquidity picture.

AI Insight: FLNA Ratio Trends

FLNA's returns remain deeply negative across all reported quarters, though ROA improved from -70.1% in Q4 2024 to -38.1% in Q1 2026.

• ROA improved from -70.1% in Q4 2024 to -38.1% in Q1 2026, a ~32pp recovery over five quarters.

• ROIC narrowed from -81.0% in Q4 2024 to -65.6% in Q1 2026, suggesting modest capital efficiency gains.

• ROE in Q2 2024 was 13.0%, the only positive reading; all subsequent quarters show deeply negative equity returns.

⚠ TTM ROE of -114.3% is far worse than any single quarter, signaling potential one-off charges weighing on trailing results.

⚠ OpMargin and NPM are entirely absent across all periods — inability to assess core profitability is a significant data gap.

Get alerted when FLNA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for FILANA THERAPEUTICS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of FLNA

MARSHALL WACE, LLP
$3.4M2,012,543 sh
TWO SIGMA INVESTMENTS, LP
$3.4M1,988,814 sh
VANGUARD CAPITAL MANAGEMENT LLC
$3.3M1,930,943 sh
BlackRock, Inc.
$2.4M1,414,514 sh
GEODE CAPITAL MANAGEMENT, LLC
$1.0M596,242 sh
D. E. Shaw & Co., Inc.
$945.1K559,205 sh
GMT CAPITAL CORP
$760.7K450,100 sh
SUSQUEHANNA INTERNATIONAL GROUP, LLP
$755.9K447,278 sh
RENAISSANCE TECHNOLOGIES LLC
$552.2K326,759 sh
GROUP ONE TRADING, L.P.
$511.4K302,624 sh

Fund	Value	Shares
MARSHALL WACE, LLP	$3.4M	2,012,543
TWO SIGMA INVESTMENTS, LP	$3.4M	1,988,814
VANGUARD CAPITAL MANAGEMENT LLC	$3.3M	1,930,943
BlackRock, Inc.	$2.4M	1,414,514
GEODE CAPITAL MANAGEMENT, LLC	$1.0M	596,242
D. E. Shaw & Co., Inc.	$945.1K	559,205
GMT CAPITAL CORP	$760.7K	450,100
SUSQUEHANNA INTERNATIONAL GROUP, LLP	$755.9K	447,278
RENAISSANCE TECHNOLOGIES LLC	$552.2K	326,759
GROUP ONE TRADING, L.P.	$511.4K	302,624

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put FLNA on your watchlist

Track score changes the day FILANA THERAPEUTICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is FLNA a good stock to buy?

13F Pro's AI-powered analysis of FILANA THERAPEUTICS, INC. (FLNA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for FLNA are available on the FLNA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own FLNA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling FLNA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of FILANA THERAPEUTICS, INC.'s investment landscape.